Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04333706
Title A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)
Acronym EMPOWER
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Southern California
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Los Angeles General Medical Center RECRUITING Los Angeles California 90033 United States Details
USC/Norris Comprehensive Cancer Center RECRUITING Los Angeles California 90033 United States Details
UF Health ACTIVE_NOT_RECRUITING Gainesville Florida 32610 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field